Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cbio
Copenhagen, Denmarkcbio.dk ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Cbio has completed preclinical development of its lead product, novoleucel, a broad-spectrum T-cell therapy targeting late-stage solid tumors such as cervical cancer. The company is preparing to enter clinical trials in early 2025 and recently secured DKK 40 million (~$6M USD) financing to support this transition.[1][2] No human clinical results are available yet.
- Therapeutic areas
- Oncology
- Modalities
- T-cell therapies (cell therapy)
- Industry
- Biotech
02
Partnerships
Clinical collaboration with Karolinska Institute, Stockholm for upcoming trials
Beyond the preview
Go deeper on Cbio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cbio.